Advertisement

Tumor Biology

, Volume 37, Issue 7, pp 8841–8848 | Cite as

Investigation of FIH-1 and SOCS3 expression in KRAS mutant and wild-type patients with colorectal cancer

  • Ladan Vakil
  • Reza Najafipour
  • Nasser Rakhshani
  • Farhad Zamani
  • Arman Morakabati
  • Amir Javadi
Original Article

Abstract

Colorectal cancer (CRC) is a multistep process based on the accumulation of somatic mutations in genes such as APC and KRAS. Data on the presence of mutations in KRAS gene in CRC and its relationship with clinicopathological parameters and expression of genes involved in tumor progression are scarce. We unbiasedly examined the KRAS status in samples from 99 patients and its correlation with clinicopathological parameters such as age, sex, tumor location, lymph node metastasis, tumor stage, tumor grade, and vascular invasion. Consistent with reports of other researchers, 38.4 % of our samples harbored KRAS mutation in their genomes with preferential mutation in codon 12 (89.4 %). Nevertheless, unlike previous reports, we were not able to correlate KRAS status with clinicopathological parameters (P > 0.05) except for vascular invasion. Patients with KRAS mutation have more vascular invasion compared with patient having wild-type KRAS. Next, we investigated the expression of two tumor suppressor genes, factor-inhibiting hypoxia-inducible factor 1 (FIH-1) and suppressor of cytokine signaling (SOCS3), in both KRAS mutant and wild-type groups and looked for any correlation between their expression and clinicopathological parameters. Although the expression of both genes was not regular, none of the clinicopathological parameters were associated with the expressions of FIH-1 and SOCS3 at mRNA level (P > 0.05). However, decline in FIH-1 expression at protein level in KRAS mutant group was correlated with stage IV and grade 2 of tumor (P ≤ 0.05). Our results demonstrated that there is no or low correlation between KRAS status, FIH-1, and SOCS3 expression with epidemiologic and clinicpathological characteristics in CRC.

Keywords

Colorectal cancer KRAS mutation FIH-1 and SOCS3 

Notes

Acknowledgments

This project has been funded by Qazvin University of Medical Sciences and Iran University of Medical Sciences. The authors also thank Mehran Ghaderi and Farhad Ghoujeghi for their experimental advices.

Compliance with ethical standards

Conflicts of interest

None

References

  1. 1.
    Lievre A, Bachet JB, Boige V, Cayre A, Le Corre D, Buc E, et al. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol Off J Am Soc Clin Oncol. 2008;26(3):374–9.CrossRefGoogle Scholar
  2. 2.
    Cancer Genome Atlas N. Comprehensive molecular characterization of human colon and rectal cancer. Nature. 2012;487(7407):330–7.CrossRefGoogle Scholar
  3. 3.
    Lievre A, Bachet JB, Le Corre D, Boige V, Landi B, Emile JF, et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res. 2006;66(8):3992–5.CrossRefPubMedGoogle Scholar
  4. 4.
    De Roock W, Jonker DJ, Di Nicolantonio F, Sartore-Bianchi A, Tu D, Siena S, et al. Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. JAMA. 2010;304(16):1812–20.CrossRefPubMedGoogle Scholar
  5. 5.
    Rosty C, Young JP, Walsh MD, Clendenning M, Walters RJ, Pearson S, et al. Colorectal carcinomas with KRAS mutation are associated with distinctive morphological and molecular features. Mod Pathol Off J U S Can Acad Pathol Inc. 2013;26(6):825–34.Google Scholar
  6. 6.
    Normanno N, Tejpar S, Morgillo F, De Luca A, Van Cutsem E, Ciardiello F. Implications for KRAS status and EGFR-targeted therapies in metastatic CRC. Nat Rev Clin Oncol. 2009;6(9):519–27.CrossRefPubMedGoogle Scholar
  7. 7.
    Li Y, Ye D. Cancer therapy by targeting hypoxia-inducible factor-1. Curr Cancer Drug Targets. 2010;10(7):782–96.CrossRefPubMedGoogle Scholar
  8. 8.
    Mahon PC, Hirota K, Semenza GL. FIH-1: a novel protein that interacts with HIF-1alpha and VHL to mediate repression of HIF-1 transcriptional activity. Genes Dev. 2001;15(20):2675–86.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Albarosa R, Colombo BM, Roz L, Magnani I, Pollo B, Cirenei N, et al. Deletion mapping of gliomas suggest the presence of two small regions for candidate tumor-suppressor genes in a 17-cM interval on chromosome 10q. Am J Hum Genet. 1996;58(6):1260–7.PubMedPubMedCentralGoogle Scholar
  10. 10.
    Wang E, Zhang C, Polavaram N, Liu F, Wu G, Schroeder MA, et al. The role of factor inhibiting HIF (FIH-1) in inhibiting HIF-1 transcriptional activity in glioblastoma multiforme. PLoS One. 2014;9(1):e86102.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Matsuyama H, Pan Y, Yoshihiro S, Kudren D, Naito K, Bergerheim US, et al. Clinical significance of chromosome 8p, 10q, and 16q deletions in prostate cancer. Prostate. 2003;54(2):103–11.CrossRefPubMedGoogle Scholar
  12. 12.
    Kees UR, Heerema NA, Kumar R, Watt PM, Baker DL, La MK, et al. Expression of HOX11 in childhood T-lineage acute lymphoblastic leukaemia can occur in the absence of cytogenetic aberration at 10q24: a study from the Children’s Cancer Group (CCG). Leukemia. 2003;17(5):887–93.CrossRefPubMedGoogle Scholar
  13. 13.
    Ke Q, Kluz T, Costa M. Down-regulation of the expression of the FIH-1 and ARD-1 genes at the transcriptional level by nickel and cobalt in the human lung adenocarcinoma A549 cell line. Int J Environ Res Public Health. 2005;2(1):10–3.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Liu CJ, Tsai MM, Hung PS, Kao SY, Liu TY, Wu KJ, et al. miR-31 ablates expression of the HIF regulatory factor FIH to activate the HIF pathway in head and neck carcinoma. Cancer Res. 2010;70(4):1635–44.CrossRefPubMedGoogle Scholar
  15. 15.
    Chen T, Ren Z, Ye LC, Zhou PH, Xu JM, Shi Q, et al. Factor inhibiting HIF1alpha (FIH-1) functions as a tumor suppressor in human colorectal cancer by repressing HIF1alpha pathway. Cancer Biol Ther. 2015;16(2):244–52.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Larsen L, Ropke C. Suppressors of cytokine signalling: SOCS. APMIS. 2002;110(12):833–44.CrossRefPubMedGoogle Scholar
  17. 17.
    O’Shea JJ, Gadina M, Schreiber RD. Cytokine signaling in 2002: new surprises in the JAK/STAT pathway. Cell. 2002;109(Suppl):S121–31.CrossRefPubMedGoogle Scholar
  18. 18.
    He B, You L, Uematsu K, Zang K, Xu Z, Lee AY, et al. SOCS-3 is frequently silenced by hypermethylation and suppresses cell growth in human lung cancer. Proc Natl Acad Sci U S A. 2003;100(24):14133–8.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Kamizono S, Hanada T, Yasukawa H, Minoguchi S, Kato R, Minoguchi M, et al. The SOCS box of SOCS-1 accelerates ubiquitin-dependent proteolysis of TEL-JAK2. J biol Chem. 2001;276(16):12530–8.CrossRefPubMedGoogle Scholar
  20. 20.
    Niwa Y, Kanda H, Shikauchi Y, Saiura A, Matsubara K, Kitagawa T, et al. Methylation silencing of SOCS-3 promotes cell growth and migration by enhancing JAK/STAT and FAK signalings in human hepatocellular carcinoma. Oncogene. 2005;24(42):6406–17.PubMedGoogle Scholar
  21. 21.
    Weber A, Hengge UR, Bardenheuer W, Tischoff I, Sommerer F, Markwarth A, et al. SOCS-3 is frequently methylated in head and neck squamous cell carcinoma and its precursor lesions and causes growth inhibition. Oncogene. 2005;24(44):6699–708.CrossRefPubMedGoogle Scholar
  22. 22.
    Tsiatis AC, Norris-Kirby A, Rich RG, Hafez MJ, Gocke CD, Eshleman JR, et al. Comparison of Sanger sequencing, pyrosequencing, and melting curve analysis for the detection of KRAS mutations: diagnostic and clinical implications. J Mol Diagn. 2010;12(4):425–32.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Li W, Qiu T, Zhi W, Shi S, Zou S, Ling Y, et al. Colorectal carcinomas with KRAS codon 12 mutation are associated with more advanced tumor stages. BMC Cancer. 2015;15:340.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Gonsalves WI, Mahoney MR, Sargent DJ, Nelson GD, Alberts SR, Sinicrope FA, et al. Patient and tumor characteristics and BRAF and KRAS mutations in colon cancer, NCCTG/Alliance N0147. J Natl Cancer Inst. 2014;106(7).Google Scholar
  25. 25.
    Rawluszko AA, Bujnicka KE, Horbacka K, Krokowicz P, Jagodzinski PP. Expression and DNA methylation levels of prolyl hydroxylases PHD1, PHD2, PHD3 and asparaginyl hydroxylase FIH in colorectal cancer. BMC Cancer. 2013;13:526.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Sinicrope FA, Shi Q, Smyrk TC, Thibodeau SN, Dienstmann R, Guinney J, et al. Molecular markers identify subtypes of stage III colon cancer associated with patient outcomes. Gastroenterology. 2015;148(1):88–99.CrossRefPubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2016

Authors and Affiliations

  • Ladan Vakil
    • 1
    • 2
    • 3
  • Reza Najafipour
    • 1
    • 2
  • Nasser Rakhshani
    • 3
  • Farhad Zamani
    • 3
  • Arman Morakabati
    • 4
  • Amir Javadi
    • 5
  1. 1.Department of Molecular Medicine, School of MedicineQazvin University of Medical SciencesQazvinIran
  2. 2.Cellular and Molecular Research CenterQazvin University of Medical SciencesQazvinIran
  3. 3.GI and Liver Disease Research Center, Firoozgar HospitalIran University of Medical SciencesTehranIran
  4. 4.Molecular Pathology Department of Mehr General HospitalTehranIran
  5. 5.Departments of Medical Informatics, School of Allied Medical SciencesTehran University of Medical SciencesTehranIran

Personalised recommendations